FDA may withdraw another fast-track med
Another fast-track drug is under FDA scrutiny. The Shire blood-pressure drug ProAmantine won agency approval in 1996 under its accelerated approval process. But follow-up studies required by that program--to confirm that it was really as effective as billed--were never conducted, the agency says.
Now, 14 years later, it's not only the branded version that will be affected by a withdrawal. Mylan Pharmaceuticals, Impax Laboratories, Novartis' generics unit Sandoz, Apotex and Upsher-Smith Laboratories would have to stop selling their generic copies, too.
The FDA's potential withdrawal isn't exactly a surprise to these companies, as the Wall Street Journal notes; last year, the Government Accountability Office actually mentioned ProAmantine when it scolded FDA for failing to follow up on drugs approved on the fast track. Since then, the agency wrote to Shire and the generics makers, requesting two studies to confirm the drugs' benefits. No studies materialized, the FDA says.
ProAmantine is the third fast-tracked drug to hit the FDA spotlight. Pfizer pulled its cancer drug Mylotarg in June after post-marketing studies raised new safety concerns and failed to confirm its effectiveness. And Roche's cancer drug Avastin is under scrutiny after new studies raised quest
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News Trend Report: The True Cost of API Price Rises
Download our Trend Report to discover what the current landscape of APIs and their pricing means for the pharmaceutical industry in the future. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance